Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease

Journal of Clinical Pharmacy and Therapeutics

Volumn 37, Issue 2, 2012, Pages 173-181

  Jordan, L B ^a   Vekeman, F ^b   Sengupta, A ^c   Corral, M ^d   Guo, A ^d   Duh, M S ^c  

^a Sickle Cell Disease Association of America Inc   (United States)

^b GROUPE D ANALYSE   (Canada)

^c ANALYSIS GROUP   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Compliance; Deferasirox; Deferoxamine; Persistence; Sickle cell disease

Indexed keywords

DEFERASIROX; DEFEROXAMINE;

ABDOMINAL PAIN; ADULT; ARTICLE; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DIZZINESS; DRUG EXPOSURE; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HOSPITALIZATION; HUMAN; INJECTION SITE INFECTION; INJECTION SITE REACTION; KIDNEY DYSFUNCTION; KIDNEY FAILURE; LENGTH OF STAY; LIVER DYSFUNCTION; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAID; NAUSEA; NEUTROPENIA; PATIENT COMPLIANCE; RASH; SICKLE CELL ANEMIA; SIDE EFFECT; SKIN BRUISING; TASTE DISORDER; VOMITING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA, SICKLE CELL; BENZOATES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DEFEROXAMINE; FEMALE; FLORIDA; HOSPITALIZATION; HUMANS; IRON CHELATING AGENTS; KAPLAN-MEIER ESTIMATE; MALE; MEDICAID; MEDICATION ADHERENCE; MIDDLE AGED; MISSOURI; NEW JERSEY; RETROSPECTIVE STUDIES; TRIAZOLES; UNITED STATES; YOUNG ADULT;

EID: 84857997579     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2011.01276.x     Document Type: Article

References (36)

1. Gabutti V, Piga A Results of long-term iron-chelating therapy. Acta Haematologica, 1996;95:26-36. (Pubitemid 26071428)
2. Kushner JP, Porter JP, Olivieri NF (2001) Secondary iron overload. Education Program of the American Society of Hematology, 47-61.
3. Harvard Medical School. Effects of iron overload: hemochromatosis, tranfusional iron overload. Available at: http://sickle.bwh.-harvard.edu/index. html (accessed February 2010).
4. Olivieri NF, Brittenham GM Iron-chelating therapy and the treatment of thalassemia. Blood, 1997;89:739-761. (Pubitemid 27121266)
5. Porter JB Practical management of iron overload. Review. British Journal of Haematology, 2001;2:239-252. (Pubitemid 34203484)
6. Cappellini MD, Cohen A, Piga A et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood, 2006;107:3455-3462.
7. Piga A, Galanello R, Forni GL et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Heamatologica, 2006;91:873-880. (Pubitemid 44023139)
8. Porter J, Vichinsky E, Rose C (2004) A phase II study with ICL670 (Exjade®), a oncedaily oral iron chelator, in patients with various transfusion-dependent anaemias and iron overload. 46th American Society of Haematology meeting, San Diego, USA, 4-7 December 2004 [abstract 3193].
9. Mahesh S, Ginzburg Y, Verma A Iron overload in myelodysplastic syndromes. Leukemia and Lymphoma, 2008;49:427-438. (Pubitemid 351298326)
10. Shashaty G, Frankewich R, Chakraborti T et al. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis. Oncology (Williston Park), 2006;20:1799-1806.
11. Deferasirox (Exjade®) full prescribing information. Available at: http://www.pharma.us.novartis.com/product/pi/pdf/exjade.pdf (accessed 2 February 2010).
12. Rebulla P Transfusion reactions in thalassemia. A survey from the Cooleycare programme. The Cooleycare Cooperative Group. Haematologica, 1990;75:122-127. (Pubitemid 20359678)
13. Giardina PJ, Grady RW Chelation therapy in beta-thalassemia: an optimistic update. Seminars in Hematology, 2001;38:360-366. (Pubitemid 32995605)
14. Goldberg SL Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. Leukemia Research, 2007;31:S16-S22. (Pubitemid 350137503)
15. Hasan SP, Hashmi S, Alhassen M, Lawson W, Castro O Depression in sickle cell disease. Journal of the National Medical Association, 2003;95:533-537. (Pubitemid 37107831)
16. Alymara V, Bourantas D, Chaidos A et al. Effectiveness and safety of combined iron chelation therapy with deferoxamine and deferiprone. The Hematology Journal, 2004;5:475-479. (Pubitemid 40045280)
17. Abetz L, Baladi JF, Jones P, Rofail D The impact of iron overload and its treatment on quality of life: results from a literature review. Health and Quality of Life Outcomes, 2006;4:73.
18. Rofail D, Muriel V, Trudeau E et al. (2006) Health-related quality of life is compromised in patients with iron overload receiving infusion treatment: US and UK SF-36 and CHQ scores compared with matched population norms. 11th congress of the European Hematology Association, Amsterdam, 15-18 June 2006 [abstract 0809].
19. Cappellini MD, Bejaoui M, Agaoglu L et al. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clinical Therapeutic, 2007;29:909-917. (Pubitemid 47241173)
20. Porter JB, Bowden D, Ganser A et al. (2008a) Satisfaction and adherence significantly improves in patients with betathalassemia and myelodysplastic syndromes treated with deferasirox (Exjade®). Blood (ASH Annual Meeting Abstracts);112. Abstract 1306.
21. Porter JB, Bowden D, Ganser A et al. (2008b) Improved health-related quality of life in patients with hematological disorders receiving deferasirox (Exjade®). Blood (ASH Annual Meeting Abstracts);112. Abstract 1307.
22. Vichinsky E, Pakbaz Z, Onyekwere O et al. Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial. Acta Haematologica, 2008;119:133-141. (Pubitemid 351896547)
23. De Abreu Lourenco R, Osborne R, Dalton A et al. (2005) An oral iron chelator and quality of life. 47th American Society of Haematology meeting, Atlanta USA, 10-13 December, 2005 [abstract 5553].
24. Delea TE, Sofrygin O, Baladi J-F et al. (2006) Chelation therapy with deferasirox versus deferoxamine in transfusion-dependent sickle-cell disease: a cost effectiveness analysis from the US perspective. 11th congress of the European Hematology Association, Amsterdam, 15-18 June 2006 [abstract 0003].
25. Karnon J, Tolley K, Oyee J, Jewitt K, Ossa D, Akehurst R Cost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United Kingdom. Current Medical Research and Opinion, 2008;24:1609-1621. (Pubitemid 351929059)
26. McLeod C, Fleeman N, Kirkham J et al. Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. Health Technology Assessment, 2009;13:iii-iv, ix-xi, 1-121.
27. Alvarez O, Rodriguez-Cortes H, Robinson N et al. Adherence to deferasirox in children and adolescents with sickle cell disease during 1-year of therapy. Journal of Pediatric Hematology/Oncology, 2009;31:739-744.
28. Raphael JL, Bernhardt MB, Mahoney DH, Mueller BU Oral iron chelation and the treatment of iron overload in a pediatric hematology center. Pediatric Blood and Cancer, 2009;52:616-620.
29. Faris RJ, McCrone D, Mody-Patel N et al. (2007) Compliance and persistency with a new oral iron chelator in patients with myelodysplastic syndromes. 43rd American Society of Clinical Oncology Annual Meeting, June 1-5, Chicago Illinois, 2007 [abstract 17510].
30. Rogovik AL, Li Y, Kirby MA et al. Admission and length of stay due to painful vasoocclusive crisis in children. American Journal of Emergency Medicine, 2009;27:797-801.
31. Adams-Graves P, Ostric EJ, Martin M et al. Sickle cell hospital unit: a disease-specific model. Journal of Healthcare Management, 2008;53:305-315.
32. Raphael JL, Kamdar A, Wang T et al. Day hospital versus inpatient management of uncomplicated vaso-occlusive crises in children with sickle cell disease. Pediatric Blood & Cancer, 2008;51:398-401.
33. Wahl S, Quirolo KC Current Issues in blood transfusion for sickle cell disease. Current Opinion in Pediatrics, 2009;21:15-21.
34. Weissman L, Treadwell M, Vichinsky E Evaluation of home desferal care in transfusion-dependent children with thalassemia and sickle cell disease (SCD). Journal of Pediatric Hematology/Oncology, 1997;4:61-68. (Pubitemid 27212180)
35. Arboretti R, Tognoni G, Alberti D Pharmacosurveillance and quality of care of thalassaemic patients. A large scale epidemiologic survey. European Journal of Clinical Pharmacology, 2001;56:915-922. (Pubitemid 33788570)
36. Delea TE, Edelsberg J, Sofrygin O et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion, 2007;47: 1919-1929. (Pubitemid 47438560)